A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma

被引：0

作者：

Sun Jin Sym

Dae Ho Lee

Hye Jin Kang

Seung Hyun Nam

Ho Young Kim

Seok Jin Kim

Hyeon Seok Eom

Won Seog Kim

Cheolwon Suh

机构：

[1] Asan Medical Center,Department of Internal Medicine

[2] University of Ulsan College of Medicine,Department of Medicine

[3] Korea Institute of Radiological and Medical Sciences,Department of Internal Medicine

[4] Seoul Veterans Hospital,Department of Internal Medicine, Sacred Heart Hospital

[5] College of Medicine,Department of Internal Medicine

[6] Hallym University,Hematology–Oncology Clinic, Research Institute and Hospital

[7] College of Medicine,Department of Medicine, Samsung Medical Center

[8] Korea University,Department of Internal Medicine

[9] National Cancer Center,undefined

[10] School of Medicine,undefined

[11] Sungkyunkwan University,undefined

[12] Gachon University Gil Hospital,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2009年 / 64卷

关键词：

Oxaliplatin; Lymphoma; Salvage therapy; Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：27 / 33

页数：6

共 50 条

[1] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma
Sym, Sun Jin
Lee, Dae Ho
Kang, Hye Jin
Nam, Seung Hyun
Kim, Ho Young
Kim, Seok Jin
Eom, Hyeon Seok
Kim, Won Seog
Suh, Cheolwon
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) : 27 - 33
[2] A Multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory/relapsed aggressive non-Hodgkin's lymphoma
Sym, Sun Jin
Kang, Hye Jin
Nam, Seung-Hyun
Kim, Hoyoung
Kim, Seok Jin
Eom, Hyeon Seok
Kim, Won Seog
Suh, Cheolwon
[J]. BLOOD, 2007, 110 (11) : 1010A - 1010A
[3] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with refractory/relapsed aggressive non-Hodgkins lymphoma: Preliminary results
Sym, S. J.
Kang, H. J.
Nam, S. H.
Kim, H. Y.
Kim, S. J.
Eom, H. S.
Kim, W. S.
Suh, C. W.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 268 - 269
[4] A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma
Young-Woong Won
Hyewon Lee
Hyeon-Seok Eom
Jin Seok Kim
Cheolwon Suh
Dok Hyun Yoon
Jung Yong Hong
Hye Jin Kang
Jae Hoon Lee
Won Seog Kim
Seok Jin Kim
Won-Sik Lee
Myung Hee Chang
Young Rok Do
Jun Ho Yi
Inho Kim
Jong-Ho Won
Kyoungha Kim
Sung Yong Oh
Jae-Cheol Jo
[J]. Annals of Hematology, 2020, 99 : 255 - 264
[5] A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma
Won, Young-Woong
Lee, Hyewon
Eom, Hyeon-Seok
Kim, Jin Seok
Suh, Cheolwon
Yoon, Dok Hyun
Hong, Jung Yong
Kang, Hye Jin
Lee, Jae Hoon
Kim, Won Seog
Kim, Seok Jin
Lee, Won-Sik
Chang, Myung Hee
Do, Young Rok
Yi, Jun Ho
Kim, Inho
Won, Jong-Ho
Kim, Kyoungha
Oh, Sung Yong
Jo, Jae-Cheol
[J]. ANNALS OF HEMATOLOGY, 2020, 99 (02) : 255 - 264
[6] High-dose ifosfamide and etoposide infusion plus methylprednisolone for refractory or relapsed aggressive non-Hodgkin's lymphoma
Salar, A
Martino, R
Altés, A
Sureda, A
Brunet, S
Sierra, J
[J]. HAEMATOLOGICA, 2000, 85 (02) : 217 - 219
[7] Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma
Machover, D
Delmas-Marsalet, B
Misra, SC
Gumus, Y
Goldschmidt, E
Schilf, A
Frénoy, N
Emile, JF
Debuire, B
Guettier, C
Farrokhi, P
Boulefdaoui, B
Norol, F
Parquet, N
Ulusakarya, A
Jasmin, C
[J]. ANNALS OF ONCOLOGY, 2001, 12 (10) : 1439 - 1443
[8] Cologne high-dose sequential chemotherapy in relapsed and refractory aggressive non-Hodgkin's lymphoma results of multicenter phase II study
Josting, A
Sieniawski, M
Staak, J
Diehl, V
Engert, A
[J]. ANNALS OF ONCOLOGY, 2005, 16 : 183 - 183
[9] A phase II trial of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma.
Mey, UJM
Strehl, JW
Orlopp, KS
Flieger, D
Birkmann, J
Ho, A
Kaiser, U
Neubauer, A
Glasmacher, AG
Schmidt-Wolf, IGH
[J]. BLOOD, 2004, 104 (11) : 238B - 238B
[10] Dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma: Updated results of a multicenter phase II trial.
Mey, UJM
Flieger, D
Birkmann, J
Neubauer, A
Ho, AD
Kaiser, U
Wilhelm, M
Haarmann, G
Hahn, C
Strehl, JW
Glasmacher, AG
Schmidt-Wolf, IGH
[J]. BLOOD, 2003, 102 (11) : 300B - 301B

← 1 2 3 4 5 →